Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.625
High: 0.625
Low: 0.625
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

Mon, 29th Oct 2018 10:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC, up 4.7%. The Asia-focused bank reported an "encouraging" third quarter with consensus beating profit. For the three months ended September, pretax profit rose 28% to USD5.92 billion from USD4.62 billion the year prior. Excluding the impact of currency translation, pretax profit rose 16% on the year before. Revenue rose 1.6% to USD13.80 billion from USD13.58 billion the year before. Revenue performance was driven by "strong" growth in all of HSBC's three main global businesses. Shore Capital called HSBC's third-quarter results strong, saying adjusted pretax profit of USD6.19 billion, up 16% on year, was 8% better than consensus at USD5.73 billion and 6% better than Shore's own forecast of USD5.86 billion. Group operating expenses decreased 6.8% to USD7.97 billion from USD8.55 billion the year before. This is largely due the bank's significant items decreasing to USD228 million from USD762 million. The large drop in one-off costs included the non-recurrence of "costs to achieve", which had been USD700 million in the year-ago comparative period. ----------Shire, up 2.5%. Japanese drugmaker Takeda Pharmaceutical said it is considering selling an experimental inflammatory bowel disease drug that is under development by its takeover target Shire. Takeda confirmed its discussion with the European Commission regarding potential overlap between its marketed product Entyvio and Shire's pipeline compound SHP647. SHP647 is a human monoclonal antibody that targets mucosal addressin cell adhesion molecule, which is currently undertaking phase III clinical trials. Takeda has proposed a potential divestment of SHP647 and associated rights. Takeda confirmed on Monday that there are no discussions with the European Commission regarding any other marketed products or assets in the pipeline.----------FTSE 100 - LOSERS----------Just Eat, down 5.2%. Peel Hunt downgraded the online takeaway platform to Sell from Buy. The broker said the rise of rivals Uber and Deliveroo could lead to the demise of Just Eat, given the two can outspend the FTSE 100 constituent and outperform in the smartphone space. Bloomberg in September reported that ride-hailing app Uber - which also offers a food delivery service Uber Eats - was in early discussions with Deliveroo, as part of its strategy to invest and partner with rivals ahead of its planned initial public offering next year.----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 20%. The cancer-focused pharmaceutical company's shares rose after a key research study demonstrated positive results for its Nuvec delivery system. Since June, N4 Pharma has conducted a research study to determine the level of immune response Nuvec can deliver, using both messenger RNA and plasmid DNA when combined with the antigen Ovalbumin. The results demonstrates that the Nuvec themselves have a clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA antigens compared to other delivery systems. As Nuvec will not require an additional adjuvant when formulating a vaccine when used as a delivery system, this could lead to reduced production costs for a final vaccine, as less antigen would be required. In addition, the level of immune response generated by Nuvec particles is within acceptable levels, showing no adverse toxicity.----------Lok'n Store, up 10%. The storage company said its earnings grew in its recently ended financial year following a rise in occupancy and store numbers. Lok'n Store said pretax profit in the year to the end of July improved to GBP5.3 million from GBP4.0 million reported a year earlier, as revenue rose to GBP17.8 million from GBP16.7 million. The company noted the result was driven by occupancy increases in both old and new stores. Tight control over operating costs led to a 2% increase in self-storage margins, which has also contributed in pushing the company's profit to "record level". Lok'nStore declared an annual dividend of 11 pence per share, up 10% from 10p paid the year prior.----------OTHER MAIN MARKET AND AIM - LOSERS----------Warpaint Group, down 43%. The colour cosmetics supplier said the UK market has remained challenging for the company with softening sales, even as it expects a rise in profit and revenue for 2018. Warpaint said its UK market, which accounted for 44% of group's sales in the first half of the year, saw further softening following the end of the interim period due to retailers reducing their stock levels and Christmas orders. The group said the reduction in previously anticipated UK sales will hurt its performance for 2018, which will not be completely offset by an outperformance in its sales territories overseas. As at September 30, sales in the US were up 60% compared to the same period in 2017, and sales in the EU were up 14% year-on-year.----------Gama Aviation, down 17%. The aviation service provider lowered its full-year expectations after trading in some of its divisions has not improved "sufficiently" during the second half of 2018. Gama said it now expects the annual underlying operating profit to be USD3 million below its original expectations. In 2017, Gama generated underlying operating profit of USD18.7 million. On a divisional basis, the company's Air unit saw stable performance in Europe, Middle East & Asia. However, profit from the US is now below Gama's expectations due to slower-than-anticipated growth in charter and aircraft management revenue. In Asia, Gama's associate China Air Services has continued to underperform with the unexpected loss of contracts significantly harming margins. ----------
More News
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more
7 Dec 2023 18:28

TRADING UPDATES: N4 Pharma hails "encouraging" siRNA research

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
7 Dec 2023 13:20

N4 Pharma posts optimistic Nuvec research update

(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on developing the Nuvec delivery system for cancer treatments and vaccines, issued an optimistic update on its ongoing in-vitro siRNA research efforts on Thursday.

Read more
1 Dec 2023 14:29

TRADING UPDATES: N4 launches investor hub; Capricorn production falls

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
28 Sep 2023 13:28

N4 Pharma picks up controlling interest in Nanogenics

(Sharecast News) - Pharmaceutical firm N4 Pharma announced the acquisition of a controlling interest in Nanogenics on Thursday.

Read more
28 Sep 2023 10:20

N4 Pharma shares fall as places shares to fund Nanogenics stake buy

(Alliance News) - N4 Pharma PLC on Thursday said it bought a controlling interest in Nanogenics Ltd, a company with a lipid and peptide-based delivery system called Liptide.

Read more
12 Sep 2023 13:43

N4 Pharma interim loss narrows slightly as business outreach ongoing

(Alliance News) - N4 Pharma PLC on Tuesday said its business outreach is ongoing as it continued to work on getting Nuvec, its delivery system for vaccines and cancer treatment, into clinic.

Read more
25 Jul 2023 12:08

LONDON MARKET MIDDAY: Miners lift FTSE 100 as Fed meeting kicks off

(Alliance News) - Stock prices in London were largely higher at midday on Tuesday, with stimulus talks in China helping lift the mood, as attention turns to the US Federal Reserve which begins its two-day monetary policy meeting later.

Read more
25 Jul 2023 10:12

N4 Pharma shares soar on further patent grant for Nuvec in US

(Alliance News) - N4 Pharma PLC on Tuesday saw its shares rise, as it celebrated a patent grant for Nuvec in the US.

Read more
25 Jul 2023 10:04

AIM WINNERS & LOSERS: N4 Pharma shares jump on grant of US patent

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
27 Jun 2023 12:13

IN BRIEF: N4 Pharma expands Professor Yu partnership on grant award

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Says it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council. Professor Chengzhong Yu, senior group leader at the Australian Institute for Bioengineering & Nanotechnology, has been awarded an AUD402,115 grant - around GBP211,366 - to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid therapies.

Read more
25 Apr 2023 16:19

TRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facility

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
25 Apr 2023 10:30

AIM WINNERS & LOSERS: FireAngel 2023 earnings below expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
18 Apr 2023 14:20

TRADING UPDATES: Journeo extends contract; Biome completes fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Apr 2023 13:13

N4 Pharma reports progress with siRNA work

(Sharecast News) - N4 Pharma updated the market on its ongoing research work on gene-silencing technology siRNA on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.